EUVIMED · CrossrefZeitschrift
Immunotherapy
ISSN 1750-743X · Informa UK Limited
Neueste Artikel
Perioperative immunotherapy in muscle-invasive bladder cancer: a narrative review of neoadjuvant, adjuvant, and antibody-drug conjugate-based strategies
Tumor microenvironment modulation for immunotherapy in colorectal cancer: integrating glycosylation into precision immuno-oncology
Tumor-associated neutrophils in gastric cancer: dual roles with promising prognostic and therapeutic potential
Next-generation dendritic cell and exosome vaccines in NSCLC: integrating personalized medicine, nanotechnology, AI, and microfluidics for enhanced immunotherapy
Cost-effectiveness analysis of tarlatamab as second-line therapy for small-cell lung cancer after platinum-based chemotherapy
Co-existent autoimmune diseases in people with multiple sclerosis and a review on choice of immunotherapy
Bacterial ghosts: next-generation biological platforms for targeted cancer therapy and immunomodulation
Nanobodies as next-generation antigen recognition domains for CAR-based cellular immunotherapies in cancer
Target engagement without clinical benefit: a systematic review, mechanism-concordant meta-analysis, and research agenda for Parkinson’s disease immunotherapy
Fostamatinib in immune thrombocytopenia: real-world experience in European countries
Macrophage-directed immunotherapy in Inflammatory bowel disease: advances in reprogramming intestinal phagocytes
Real-world outcomes of interleukin-17 inhibitors in familial Mediterranean fever-associated inflammatory conditions: a retrospective study
Knockdown of MAP7D2 regulates the immune-modulatory function mediated by CD8+ T cells and inhibits LUAD progression
The potential of PDHA1 as a cuproptosis-related prognostic and immune biomarker in lung squamous cell carcinoma
Real-world efficacy and safety of neoadjuvant immunochemotherapy in patients with triple-negative breast cancer
Addressing socioeconomic barriers to immunotherapy access for non-small cell lung cancer in Japan
Baseline circulating immunophenotype as a predictor of immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors
Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer
Real-world utilization of immune checkpoint inhibitors in medicare-eligible patients with triple-negative breast cancer in the United States
Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma
Liquid–liquid phase separation-related gene can predict prognosis and influence immune microenvironment in acute myeloid leukemia
Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling
Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma
Injection-based safety of aqueous venom immunotherapy during venom extract shortage: impact of forced depot-to-aqueous switching
Efficacy and safety of chimeric antigen receptor T-cell therapy in primary central nervous system lymphoma: a systematic review and meta-analysis
Low-dose interleukin-2 combined with thalidomide for a severe cutaneous immune-related adverse event associated with PD-1/CTLA-4 bispecific antibody therapy: a case report
Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1–negative cancers: a systematic review and meta-analysis
From receptor biology to therapy: importance of different EGFR mutations in the development of targeted cancer therapies
Bromodomain inhibitors in autoimmune diseases
EUVIMED